Edition:
United States

People: Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

64.50USD
26 May 2017
Change (% chg)

$-0.06 (-0.09%)
Prev Close
$64.56
Open
$64.37
Day's High
$64.75
Day's Low
$64.31
Volume
4,021,883
Avg. Vol
9,222,108
52-wk High
$88.85
52-wk Low
$63.88

Bischofberger, Norbert 

Dr. Norbert W. Bischofberger, Ph.D., is Executive Vice President of Research and Development, Chief Scientific Officer of Gilead Sciences Inc. Dr. Bischofberger joined Gilead in 1990 and has served as Executive Vice President, Research and Development since 2000 and Chief Scientific Officer since 2007. Prior to joining Gilead, Dr. Bischofberger was a Senior Scientist in Genentech, Inc.’s DNA Synthesis group from 1986 to 1990. He received his Ph.D. in Organic Chemistry at the Eidgenossische Technische Hochschule (ETH) in Zurich, Switzerland and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside’s lab at Harvard University in Cambridge, Massachusetts.

Basic Compensation

Total Annual Compensation, USD 1,044,230
Restricted Stock Awards, USD 1,935,730
Long-Term Incentive Plans, USD --
All Other, USD 3,189,510
Fiscal Year Total, USD 6,169,470

Options Compensation

  Quantity Market Value
Exercisable 736,500 25,416,500.00
Unexercisable 698,500 19,189,600.00
Exercised 540,000 32,892,400.00
Name Fiscal Year Total

John Martin

10,442,400

John Milligan

13,935,200

Robin Washington

5,068,060

Kevin Young

5,639,670

Norbert Bischofberger

6,169,470

Gregg Alton

5,325,570
As Of  30 Dec 2016